Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have always been excluded. Apart from the clinical trials, more HCC patients are currently being treated in daily practice, given that these treatments are highly effective and involve well-tolerated regimens. Large scale, real-world studies have demonstrated potentially suboptimal antiviral treatment efficacy in HCC patients who received DAAs. It is postulated that the impairment of the bioavailability of DAAs may account for the inferior treatment response. However, the results could not be generalized across all studies. The differing results were attributed to diverse patient characteristics, suboptimal regimens or imprecise definitions of active cancer statuses at the time of treatment initiation. Additional large-scale studies that utilize the treatment of choice in clearly defined HCC patients with different disease severities are warranted to clarify the issue.
Abstract
During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have always been excluded. Apart from the clinical trials, more HCC patients are currently being treated in daily practice, given that these treatments are highly effective and involve well-tolerated regimens. Large scale, real-world studies have demonstrated potentially suboptimal antiviral treatment efficacy in HCC patients who received DAAs. It is postulated that the impairment of the bioavailability of DAAs may account for the inferior treatment response. However, the results could not be generalized across all studies. The differing results were attributed to diverse patient characteristics, suboptimal regimens or imprecise definitions of active cancer statuses at the time of treatment initiation. Additional large-scale studies that utilize the treatment of choice in clearly defined HCC patients with different disease severities are warranted to clarify the issue.
참고문헌 (19)
- Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Yu ML, "Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients : a model for prioritization of treatment", Clin Cancer Res, 23, pp.1690~1697 (2017)
- Ioannou GN, "HCV eradication induced by directacting antiviral agents reduces the risk of hepatocellular carcinoma", J Hepatol, pp.030~ (2017)[DOI]
- Huang JF, "The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies-a multicenter prospective trial", J Hepatol, 54, pp.219~226 (2011)
- Curry MP, "Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation : an open-label study", Gastroenterology, 148, pp.100~107 (2015)[DOI]
- Saberi B, "Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma", Hepatology, 66, pp.661~663 (2017)
- Soria A, "Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals", Hepatology, 66, pp.992~994 (2017)
- Prenner SB, "Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals", J Hepatol, 66, pp.1173~1181 (2017)
- Beste LA, "Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma", J Hepatol, 67, pp.32~39 (2017)
- Konjeti VR, "Interaction between hepatocellular carcinoma and hepatitis C eradication with direct-acting antiviral therapy", Curr Treat Options Gastroenterol, 16, pp.203~214 (2018)
- Furihata T, "Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides", Antimicrob Agents Chemother, 58, pp.4555~4564 (2014)
- Wlcek K, "The analysis of organic anion transporting polypeptide(OATP)mRNA and protein patterns in primary and metastatic liver cancer", Cancer Biol Ther, 11, pp.801~811 (2011)
- Huang CF, "Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication", J Gastroenterol Hepatol (2018)[DOI]
- Sachdeva M, "Immunology of hepatocellular carcinoma", World J Hepatol, 7, pp.2080~2090 (2015)
- Chang CY, "Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease", Medicine (Baltimore), 96, pp.e6128~ (2017)
- Wei B, "Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia : a systematic review and meta-analysis", BMJ Open Gastroenterol, 5, pp.e000207~ (2018)
- Ji F, "Systematic review with meta-analysis : effectiveness and tolerability of interferonfree direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia", Aliment Pharmacol Ther, 47, pp.550~562 (2018)
- Ogawa E, "Effectiveness and safety of DAA treatment for CHC patients with previous HCC: a REAL-C study", American Association for the Study of Liver Diseases, A51~ (2018)